TG Therapeutics, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: New York NY United States (1993)

Organization Overview

First Clinical Trial
2012
NCT01647971
First Marketed Drug
2021
umbralisib
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

TG Therapeutics | TG Therapeutics, Inc. | TG THERAPS

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Disease Progression (Phase 2)

Gastrointestinal Stromal Tumors (Phase 1)

Hodgkin Disease (Phase 1)

Leukemia (Phase 3)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 3)

Leukemia, Lymphoid (Phase 3)

Lymphoma (Phase 3)

Lymphoma, B-Cell (Phase 2)

Lymphoma, B-Cell, Marginal Zone (Phase 2)

Lymphoma, Follicular (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 3)

Lymphoma, Mantle-Cell (Phase 3)

Lymphoma, Non-Hodgkin (Phase 3)

Lymphoma, T-Cell, Peripheral (Phase 1)

Multiple Sclerosis (Phase 3)

Multiple Sclerosis, Relapsing-Remitting (Phase 2)

Sclerosis (Phase 3)

Waldenstrom Macroglobulinemia (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 40
  • # of Trial APIs: 26